Tyenne (tocilizumab-aazg subcutaneous injection – Fresenius Kabi) — Cigna

Initial criteria

• Patient age > 2 years
• Patient has tried ONE other systemic therapy for this condition (examples include methotrexate, sulfasalazine, leflunomide, or a nonsteroidal anti-inflammatory drug [NSAID]) OR a previous trial of one biologic other than the requested drug
• Criteria continue beyond this excerpt but initial elements listed are explicit in this section

Approval duration

6 months (initial)